DNA SCRIPT

Company Overview

DNA Script, founded in 2014, is developing next-generation DNA synthesis technology based on an enzymatic and nucleotide chemistry platform. The synthesis technology is to be used for synthetic biology applications, including the development of new therapeutics, sustainable chemical production, better crops, and data storage. The company has demonstrated the integration of innovations in instrumentation, enzyme engineering, and surface and nucleotide chemistries resulting in the development of SYNTAX, the world’s first benchtop DNA printer equipped with enzymatic technology. The company has offices in France and the U.S. with distributors located in China, Hong Kong, India, Israel, Japan, the Middle East, Singapore, South Korea, Taiwan, and Turkey.

In January 2018, DNA Script reached a licensing agreement with Dynamic Combinatorial Chemistry that covered unique DNA building blocks used in enzymatic DNA synthesis. These building blocks are reversible terminator nucleotides with cleavable protective groups.

In February 2019, DNA Script announced that it had achieved the first enzymatic synthesis of a high-purity 200-nucleotide strand of DNA.

Company's Business Segments

• DNA Synthesis (EDS) Technology : The company manufactures de novo synthetic nucleic acids using enzymatic DNA synthesis (EDS) technology.